Comparative studies on novel combinations of pregabalin plus venlafaxine with standard diazepam and marketed combination of alprazolam plus sertraline for anxiety disorders

Rahul P. Pol, ATUL RAMCHANDRA CHOPADE1,2, Nilofar S. Naikwade1, R. J. Dias3

Abstract


Summary Objective- In present study, eleven novel dose combinations of Pregabalin & Venlafaxine from minimum effective dose to higher anxiolytic dose were taken for assessment of anxiolytic activity in Swiss mice.

Method — Classical animal models of anxiety vise: Elevated plus-maze model and Light & Dark Exploration test Apparatus. Diazepam was used as a standard anxiolytic. In addition the combinations were also compared with a fixed dose marketed combination of Alprazolam & Sertraline (Anxit Plus).

Result — The results of the study reveal that combinations of Pregabalin & Venlafaxine (serotonin norepinephrine reuptake inhibitor) have better anxiolytic efficacy, which is comparable to Diazepam and Alprazolam-Sertraline combination.

Conclusion- Further clinical studies are required for getting better idea about efficacy and clinical utility of Pregabalin-Venlafaxine combination.


Keywords


Combination of pregabalin plus venlafaxine; diazepam; alprazolam; sertraline and anxiety.

Full Text:

PDF

References


Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):593-602.

Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006; 67: 20-26.

Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009; 70: 25-31.

Westenberg HG. Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009; 14(2): 24-33.

Gupta YK, Prakash A. Therapeutic potential of 5-HT receptor modulators. Ind J Pharmacol. 1994; 26: 94-107.

Lee SI, Keltner NL. Serotonin and norepinephrine reuptake inhibitors (SNRIs): Venlafaxine and Duloxetine. Perspect. Psychi. Care. 2006.

Driot D, Bismuth M, Maurel A, Soulie-Albouy J, Birebent J, Oustric S, Dupouy J. Management of first depression or generalized anxiety disorder episode in adults in primary care: A systematic metareview. Presse Med. 2017; 46(12): 1124-1138.

Paul JW. GABA-A receptors: a viable target for novel anxiolytics? Curr Opin Pharmacol. 2006; 6: 24-29.

Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014; 28(9):835-54.

Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J. A systematic review of pharmacoeconomic studies for pregabalin. Pain Pract. 2015; 15(1):82-94.

Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49(2):280-94.

Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985; 14: 149-167.

Rodgers RJ, Shepherd JK. Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/ dark tests of anxiety in mice. Psychopharmacology (Berl). 1993; 113: 237-242.

Hascoet M. Bourin A. New approach to Light/Dark test procedure in mice. Pharmacol Biochem Behav. 1998; 60(3): 645-653.

Bourin M, Hascoet M. The mouse light/dark box test. Eur J Pharmacol. 2003; 463: 55-65.

Gaurav Patki, Lumeng Li, Farida Allam, Naimesh Solanki, An T Dao, Karim Alkadhi, and Samina Salim, Moderate treadmill exercise rescues anxiety and depression-like behavior as well as memory impairment in a rat model of posttraumatic stress disorder. Physiol Behav. 2014; 130: 47–53.




DOI: http://dx.doi.org/10.24294/as.v1i3.977

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.